MedTrace Logo

NKG2D CAR-NK Cell Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT05247957 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2023-01-13

No results posted yet for this study

Summary

This trial will explore the maximum tolerated dose of cord blood NKG2D CAR-NK in the treatment of recurrent refractory acute myeloid leukemia in a dose-escalation manner, and observe its clinical safety and efficacy.

Conditions

  • Safety and Efficacy

Interventions

BIOLOGICAL

CAR-NK cells

NKG2DL-specific CAR-NK cells, 2 infusions on Day 0 and Day 7

Sponsors & Collaborators

  • Hangzhou Cheetah Cell Therapeutics Co., Ltd

    lead OTHER

Principal Investigators

  • Peihua Lu, MD · Hebei Yanda Lu Daopei Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
10 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-13
Primary Completion
2022-12-12
Completion
2022-12-20

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05247957 on ClinicalTrials.gov